Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy

Lancet Respir Med. 2022 Jan;10(1):e7. doi: 10.1016/S2213-2600(21)00487-2. Epub 2021 Nov 8.

Authors

Brian Lipworth¹, Rasads Misirovs², Rory Chan²

Affiliations

¹ Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK. Electronic address: b.j.lipworth@dundee.ac.uk.
² Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK.

PMID: 34762848
DOI: 10.1016/S2213-2600(21)00487-2

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adrenal Cortex Hormones
Adrenal Insufficiency* / chemically induced
Anti-Asthmatic Agents* / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects
Humans

Substances

Adrenal Cortex Hormones
Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
benralizumab